TD Cowen analyst Stacy Ku has maintained their bullish stance on MLTX stock, giving a Buy rating today.
Stacy Ku has given his Buy rating due to a combination of factors including the promising clinical programs and market potential of MoonLake Immunotherapeutics. The ongoing pivotal VELA program for sonelokimab in hidradenitis suppurativa (HS) is expected to yield significant results by mid-2025, with the potential to differentiate sonelokimab from competitors based on efficacy. Experts are optimistic about sonelokimab’s performance, suggesting it could match or surpass current market leaders.
Additionally, the initiation of the IZAR pivotal program in psoriatic arthritis (PsA) is another factor contributing to the Buy rating. The trial’s innovative design, including a Skyrizi reference arm, could provide a competitive edge in the PsA market, which is projected to grow substantially. The fast onset of action of sonelokimab in PsA patients is particularly promising, and the anticipated data could further establish its market differentiation. These strategic clinical advancements and market opportunities underpin Stacy Ku’s positive outlook on MoonLake Immunotherapeutics.
According to TipRanks, Ku is an analyst with an average return of -8.2% and a 36.07% success rate. Ku covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, VYNE Therapeutics, and KalVista Pharmaceuticals.
In another report released today, LifeSci Capital also maintained a Buy rating on the stock with a $75.00 price target.